代謝の可塑性とがん幹細胞代謝:抵抗と腫瘍発生のメカニズムとしてのグリコリシス-OXPHOSスイッチの探索
Li Qing Keoh1, Ching-Feng Chiu2, Thamil Selvee Ramasamy3
1Stem Cell Biology Laboratory, Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.
Stem cell reviews and reports
|August 29, 2025
まとめ
ガン細胞
科学分野:
- 腫瘍学
- 代謝経路
- 癌の生物学
背景:
- 代謝の可塑性により,がん細胞はストレスに適応し,腫瘍の異質化に寄与します.
- ガンの生存には,特に転移と治療の間に,糖分解と酸化リン酸化 (OXPHOS) の間の切り替えが不可欠である.
- がん幹細胞 (CSCs) のこの代謝スイッチの役割は複雑で,治療結果に影響します.
研究 の 目的:
- 腫瘍形成におけるグリコリシス-OXPHOSスイッチの役割を批判的に検討する.
- 癌幹細胞 (CSC) の可塑性および薬剤耐性に対する影響を理解する.
- CSCの代謝を標的とした新しい治療戦略を策定する.
主な方法:
- 既存の研究の文献レビューと批判的分析.
- 癌における代謝動態の検討
- 糖分解-OXPHOSスイッチとCSCに関する情報の合成
主要な成果:
- Glycolysis-OXPHOSスイッチは腫瘍形成の重要な要因であり,CSCの可塑性に影響する.
- CSCを標的とした治療戦略は 異なった結果を示し,あるものは無意識に耐性を促進している.
- これらの代謝動態を理解することは 効果的ながん治療に不可欠です
結論:
- ガン幹細胞 (CSC) の可塑性および抵抗性に大きな影響を与える.
- CSCの代謝可塑性をターゲットにすることで,がん治療の改善の可能性が生まれます.
- 治療の失敗や再発を克服するには 適した治療方法が必要です
関連する概念動画
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


